News | November 01, 2024
AstraZeneca China President currently under investigation
Our China operations continue under the leadership of the current General Manager of AstraZeneca China
Our China operations continue under the leadership of the current General Manager of AstraZeneca China
Data demonstrate the importance of protecting against serious respiratory infections caused by respiratory syncytial virus, human metapneumovirus and COVID-19
CSPC will receive an upfront payment of $100 million from AstraZeneca
Tremelimumab (Imjudo) in combination with Durvalumab (Imfinzi) is indicated for the treatment of patients with unresectable hepatocellular carcinoma
Palivizumab (Synagis) is indicated for the prevention of serious lower respiratory tract disease requiring hospitalization caused by RSV in children at high risk for RSV disease
Presidential Symposium for NIAGARA will highlight practice-changing impact of a perioperative Imfinzi-based regimen in bladder cancer
The results are an outcome of the company's focus on sustainable and profitable growth and reflects all the hard work and focus teams have put in over the years
The company will now explore a buyer for its manufacturing site and exit in due course
This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs
Recommendation based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months
Subscribe To Our Newsletter & Stay Updated
